Altimmune Q2 Net Loss $(22.8M); Raises $281.4M in Offerings

Altimmune, Inc. reported a net loss of $(22.8) million for the second quarter of 2026, an increase from $(22.1) million in the same period last year. For the first half of 2026, the net loss was $(45.4) million. The company significantly bolstered its financial position by raising $281.4 million net from public offerings and pre-funded warrants, and an additional $8.7 million net from at-the-market offerings during the first six months of 2026. This resulted in cash, cash equivalents, and restricted cash increasing to $63.1 million and total stockholders' equity rising to $474.2 million by June 30, 2026. The company also announced plans to relocate its headquarters, incurring $1.5 million in impairment charges.